

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00530-095002	Application No. 10/733,212
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Donald W. Kufe	
		Filing Date December 11, 2003	Group Art Unit 1633

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
KKH	AL	WO 02/22685 A2	03/21/2002	WIPO	C07K	16/00		
↓	AM	WO 96/03502 A2	02/08/1996	WIPO	C12N	15/12		
	AN							
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KKH	AQ	Gay et al., "Selective BRB2 SH2 Inhibitors as Anti-RAS Therapy", Int. J. Cancer, 83(2):235-241 (1999)
↓	AR	Li et al., "The Epidermal Growth Factor Receptor Regulates Interaction of the Human DF3/MUC1 Carcinoma Antigen with c-Src and β -Catenin", J. Biol. Chem., 276(38): 35239-35242 (2001)
↓	AS	Li et al., "The c-Src Tyrosine Kinase Regulates Signaling of the Human DF3/MUC1 Carcinoma-associated antigen with GSK3 β and β -Catenin", J Biol. Chem., 276(9): 6061-6084 (2001)
↓	AT	Li et al., "The Human DF3/MUC1 Carcinoma-Associated Antigen Signals Nuclear Localization of the Catenin p120 ^{cas} ", Biochem. Biophys. Res. Commun., 281:440-443 (2001)

Examiner Signature Kevin K. Hill	Date Considered May 29, 2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00530-095002	Application No. 10/733,212
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Donald W. Kufe	
		Filing Date December 11, 2003	Group Art Unit 1633

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KKH	AU	Pandy et al., "Association of the DF3/MUC1 Breast Cancer Antigen with Grb2 and the Sos/Ras Exchange Protein", <i>Can. Res.</i> , 55:4000-4003 (1995)
↓	AV	Rawcastle et al., "Tyrosine Kinase Inhibitors. 14. Structure-Activity Relationships for Methyl-amino-substituted Derivatives of 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido [3,4- <i>d</i>] pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors for the EGF Family of Growth Factors", <i>J. Med. Chem.</i> , 41:742-751 (1998)
	AW	Yamamoto et al., "Interaction of the DF3/MUC1 Breast Carcinoma-associated Antigen and β-Catenin in Cell Adhesion", <i>J. Biol. Chem.</i>, 272(19):12492-12494 (1997)

Examiner Signature Kevin K. Hill	Date Considered May 29, 2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/